Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07351045 · ClinicalTrials.gov registry record · Phase 3
A Clinical Study to Evaluate the Effects of RO7795068 in Participants With Obesity or Overweight Without Type 2 Diabetes
A Phase 3 study of Obesity or Overweight, sponsored by Hoffmann-La Roche.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 2,000
- Enrollment target
- 2
- Study locations
NCT07351045 is a Phase 3 study of Obesity or Overweight that is actively recruiting participants, run by Hoffmann-La Roche. The registered enrollment target is 2,000 participants, above the 532-participant average among 6 other Obesity or Overweight trials with a reported enrollment target (276% higher). The trial reports 2 study locations across 2 states.
The verdict
NCT07351045, a Phase 3 study of Obesity or Overweight, is actively recruiting participants, sponsored by Hoffmann-La Roche.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 2,000 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to assess the efficacy and safety of RO7795068, a dual glucagon like peptide-1 (GLP-1)/glucose-dependent insulinotropic polypeptide (GIP) receptor agonist (RA), at multiple doses compared with placebo for weight management in participants without Type 2 diabetes mellitus (T2DM) who have obesity or overweight with at least one weight-related comorbidity.
Conditions Studied
Interventions
- COMBINATION_PRODUCT Placebo
- COMBINATION_PRODUCT RO7795068
Study Locations (2)
Illinois
- Elevate Clinical Research - Gurnee
Tennessee
- Clinical Research Associates - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,000 participants |
| Start Date | 2026-03-31 |
| Est. Completion | 2028-08-28 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07351045
The ClinicalTrials.gov registry entry for NCT07351045 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 2,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 532-participant average among 6 other Obesity or Overweight trials with a reported enrollment target (276% higher). The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Obesity or Overweight appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07351045 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Illinois, Tennessee.
Frequently Asked Questions
What is clinical trial NCT07351045 about?
NCT07351045 is a clinical study titled "A Clinical Study to Evaluate the Effects of RO7795068 in Participants With Obesity or Overweight Without Type 2 Diabetes". The purpose of this study is to assess the efficacy and safety of RO7795068, a dual glucagon like peptide-1 (GLP-1)/glucose-dependent insulinotropic polypeptide (GIP) receptor agonist (RA), at multiple doses compared with placebo for weight management in participants without Type 2 diabetes mellitus...
What is the current status of trial NCT07351045?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 2,000 participants. The study started on 2026-03-31. Estimated completion is 2028-08-28.
What conditions does trial NCT07351045 study?
This clinical trial studies the following conditions: Obesity or Overweight.
What interventions are being tested in trial NCT07351045?
The interventions under investigation include: Placebo (COMBINATION_PRODUCT), RO7795068 (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT07351045?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07351045 being conducted?
This trial has 2 study locations across Illinois, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity or Overweight
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
RECRUITING · Phase 3
-
Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
RECRUITING · Phase 3
-
A Clinical Study to Evaluate the Effects of RO7795068 in Participants With Obesity or Overweight and Type 2 Diabetes
RECRUITING · Phase 3
-
A Weight Loss Study Evaluating Subcutaneous Treatment With AZD9550 and AZD6234 in Combination Against Placebo or Each of the Drugs Alone
ACTIVE NOT RECRUITING · Phase 2
-
Study of Once-Daily Oral RGT001-075 Compared With Placebo in Adults With Obesity or Are Overweight With Weight-Related Health Conditions
ACTIVE NOT RECRUITING · Phase 2
-
A Study Evaluating the Effect of Daily Oral RO7795081 in Participants With Obesity or Overweight With at Least One Weight-Related Comorbidity
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.